about
Derivation of injury-responsive dendritic cells for acute brain targeting and therapeutic protein delivery in the stroke-injured ratOrganically modified silica nanoparticles are biocompatible and can be targeted to neurons in vivoAutomated microscopy screening for compounds that partially revert cholesterol accumulation in Niemann-Pick C cells.Advances in Systemic siRNA DeliveryNonneurotropic adenovirus: a vector for gene transfer to the brain and gene therapy of neurological disordersNeuroprotective gene therapy against acute neurological insults.Gene therapy for the nervous system: challenges and new strategies.Gene therapy approaches for lysosomal storage disease: next-generation treatment.Safety study of adeno-associated virus serotype 2-mediated human acid sphingomyelinase expression in the nonhuman primate brain.Efficacy of nonviral gene transfer in the canine brain.alpha-Synuclein: a therapeutic target for Parkinson's disease?Cell and gene therapies for refractory epilepsy.Nanoparticles in the brain: a potential therapeutic system targeted to an early defect observed in many neurodegenerative diseases.Directing adenovirus across the blood-brain barrier via melanotransferrin (P97) transcytosis pathway in an in vitro model.Human neural progenitors deliver glial cell line-derived neurotrophic factor to parkinsonian rodents and aged primates.Survival advantage of neonatal CNS gene transfer for late infantile neuronal ceroid lipofuscinosis.Magnetic resonance imaging-guided delivery of adeno-associated virus type 2 to the primate brain for the treatment of lysosomal storage disorders.Long-term transgene expression in mouse neural progenitor cells modified with phiC31 integrase.Development of efficient plasmid DNA transfer into adult rat central nervous system using microbubble-enhanced ultrasound.Human synapsin 1 gene promoter confers highly neuron-specific long-term transgene expression from an adenoviral vector in the adult rat brain depending on the transduced area.Prevention of onset of Parkinson's disease by in vivo gene transfer of human hepatocyte growth factor in rodent model: a model of gene therapy for Parkinson's disease.Multifunctional nanoparticles for gene delivery and spinal cord injury.A mouse model study of toxicity and biodistribution of a replication defective adenovirus serotype 5 virus with its genome engineered to contain a decoy hyper binding site to sequester and suppress oncogenic HMGA1 as a new cancer treatment therapy.
P2860
Q27324122-F1C037D1-B9C2-4B4F-A1B2-05F1095D841CQ28478671-BA4562E9-DE8B-4685-8B7B-6E14E382973FQ33227195-463B5981-600A-4737-B5CA-62DDE6653CEFQ33613316-96B02A6E-7D2F-4B84-8268-F4BF1E446AE0Q33985663-47A9A169-3D39-42A0-9D59-1A37F1861D7AQ35038275-91E7B915-7FEF-4470-90C4-1C6629E5E48DQ35340196-E2478CCE-FD8F-427A-AACB-C4DE07651BDDQ36147475-FD4A300F-0472-4FD6-97FA-FA66C22F5604Q36147515-32B7FB9A-5FFF-403B-BBA0-560DCB089A10Q36658314-BE06D31C-B6DF-451E-A4B6-A79EBA6A44C4Q37070916-710C6C2E-9D5A-4F17-9B4F-98ACB4CEBC0DQ37211817-98048257-BA61-48EA-8260-211C5EAFBED2Q38102579-6D35C03D-CE4C-48EF-B778-1258B2DF4414Q40196760-FDE5C74E-5958-471A-A70A-D7C4F45DCDACQ40339968-312A739F-3FAC-466A-A168-10A448985E0EQ41988291-7152F655-C5CC-43FE-AFF7-BE89FFB0B24BQ42428990-1B9E859A-5336-4781-8A0E-DA50F95B6251Q43211527-CDB9B3B8-B909-42DF-B0BC-A48FE38D52B7Q44288775-DCAD7661-6B65-4862-BED0-354B28ECFD30Q45858691-909520A0-24BC-4AB0-996C-F601A45A208FQ45859214-3F9913B5-DCFC-43AF-9730-CBAD7E142206Q45875230-35990250-8DE7-472D-A432-7ECED7D2CE35Q52692695-589BD5CB-0106-404A-9559-1A3592D01F4A
P2860
description
2002 nî lūn-bûn
@nan
2002 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2002 թվականի մարտին հրատարակված գիտական հոդված
@hy
2002年の論文
@ja
2002年論文
@yue
2002年論文
@zh-hant
2002年論文
@zh-hk
2002年論文
@zh-mo
2002年論文
@zh-tw
2002年论文
@wuu
name
Critical issues in gene therapy for neurologic disease.
@ast
Critical issues in gene therapy for neurologic disease.
@en
Critical issues in gene therapy for neurologic disease.
@nl
type
label
Critical issues in gene therapy for neurologic disease.
@ast
Critical issues in gene therapy for neurologic disease.
@en
Critical issues in gene therapy for neurologic disease.
@nl
prefLabel
Critical issues in gene therapy for neurologic disease.
@ast
Critical issues in gene therapy for neurologic disease.
@en
Critical issues in gene therapy for neurologic disease.
@nl
P2093
P1433
P1476
Critical issues in gene therapy for neurologic disease.
@en
P2093
Gary Hsich
Miguel Sena-Esteves
Xandra O Breakefield
P304
P356
10.1089/10430340252837198
P577
2002-03-01T00:00:00Z